Raise closed, search for fresh raises on Seedstage

Brooklyn, NY

Advancing wearable brain stimulation technology for anxiety and depression treatment.

• Targeted FDA Clearance: OAK® is on track for FDA clearance by Summer 2025.
• Proven Track Record: Over 100,000 units of the previous device sold, generating $40M in revenue.
• Innovative Technology: Designed as a rapid, self-administered solution for anxiety and depression.
• Broad Applications: Future studies aim to measure cognitive and physical health improvements.
• Strategic Partnerships: Collaborating with experts and institutions to expand distribution and clinical validation.

Fisher Wallace is advancing its innovative wearable brain stimulation technology, OAK®, designed to address mental health challenges such as anxiety and depression. The funds raised will be utilized to complete the development, regulatory approval, and commercialization of OAK®, with a targeted FDA clearance timeline by Summer 2025. This device builds on the company’s validated success with its prior technology and introduces new features aimed at scalability and usability. Fisher Wallace also plans to extend its impact through studies targeting additional applications like cognitive function improvement and adolescent depression.

Fisher Wallace emphasizes accessibility by designing OAK® as an affordable, home-administered treatment. With its previous device achieving notable milestones, including 100,000 units sold and widespread clinical adoption, the company is well-positioned to disrupt traditional therapeutic options. The funds raised will also support expansion into new markets such as the U.S. Department of Veterans Affairs and European healthcare systems. By combining advanced neuromodulation technology with cutting-edge industrial design, Fisher Wallace seeks to redefine mental health treatment for diverse populations globally.

Company Info

Fisher Wallace Laboratories develops wearable brain stimulation devices to treat anxiety and depression, aiming for FDA clearance of its latest OAK device by 2025.

Fisher Wallace Laboratories develops wearable brain stimulation devices aimed at treating mental health conditions such as anxiety and depression. The company’s technology has been validated as one of the most rapid self-administered treatments for these conditions, with study results published in reputable medical journals. Its OAK device, currently under development, is designed to meet regulatory standards and achieve FDA clearance by 2025. Fisher Wallace has also worked to integrate its product into healthcare systems by exploring distribution partnerships with the Department of Veterans Affairs and pursuing Medicaid reimbursement in certain states.

Fisher Wallace has commercialized an earlier version of its device, selling over 100,000 units and generating $40 million in revenue. The OAK device aims to appeal to younger generations, including Gen Alpha and Gen Z, by improving cognitive and physical health alongside mood. The company is preparing to expand into European markets while leveraging clinical trial data to secure regulatory approvals. With a proven product-market fit and partnerships to scale distribution, Fisher Wallace seeks to bring innovation to mental health treatment worldwide.